Exploratory Study of Norepinephrine to Prevent Radiodermatitis in Breast Cancer Patients

Eligibility Criteria Subjects must: * be ≥ age 18 years of age with a documented pathological diagnosis of Stage Ia (T1, N0, M0), Stage Ib (T0 or 1, N1mic, M0) or Stage IIa (T\<3cm, N0, M0) infiltrating ductal or lobular carcinoma of the breast or ductal carcinoma in situ (DCIS). * be post-surgical patients scheduled to be treated with at least 40 to 50.4 Gy to the whole breast and axilla using either standard or hypofractionated radiation techniques . An additional 10-16 Gy boost to the lumpectomy region may also be delivered. All radiation treatment is to be delivered based on standard CT planning. * have the ability to understand the informed consent document. * be able to comply with protocol schedule. * have a negative serum pregnancy test (within 7 days prior to starting radiation therapy), if a female of child bearing potential. * consent to utilize medically acceptable methods of contraception throughout the study period if of child-bearing potential. Exclusion Criteria Subjects: * with unhealed surgical wounds or scars in the study treatment area (axilla). * with underlying active untreated cardiac disease (e.g. arrhythmia). * with generalized skin disorders that have required treatment within the past 6 months. * with connective tissue disorders. * with rashes, ulcerations, or poorly healed scars in the study drug application area (axilla). * with a known allergy to norepinephrine. * with known uncontrolled hypertension (repeatedly elevated BP; systolic BP \>139 or diastolic BP \>89). * with a known clinically significant abnormal ECG within the past 6 months. * receiving MAO inhibitors or antidepressants (triptyline or imipramine types). * who are pregnant or breastfeeding. * with lymphovascular space invasion on pathology. * with dermal lymphatic invasion on pathology. * with proximity of the tumor to the overlying skin as evidenced by a distance of less than 5 mm on US or MRI (if performed) and within 2 cm of the anticipated application field * diagnosis of inflammatory breast cancer. * receiving chemotherapy other than Herceptin concurrent with the radiation. * with previous radiation to the breast to be treated.